Amino Acid, Peptide, or Protein

Zymeworks Pivots to Royalty-Driven Model After Strong Ziihera Data in Gastric Cancer

9 hours ago talkbio0Tagged Biological Factors, buyback, erbB-2 Receptor, Jazz, Malignant neoplasm of stomach, milestone payments, Regulatory Filing, Royalty-Driven Model, Strategy, Ziihera, Zymeworks

Zymeworks; royalty-driven model; Ziihera; gastric cancer; HER2; biologics; milestone payments; stock buyback; biotech strategy; Jazz Pharmaceuticals; regulatory filing

Jazz and Zymeworks Bispecific Antibody Zanidatamab Delivers Practice-Changing Results in Stomach Cancer Study

1 day ago talkbio0Tagged Antibodies, Bispecific, erbB-2 Receptor, gastroesophageal adenocarcinoma, Jazz, Malignant neoplasm of stomach, orphan drug designation, Overall Survival, Pharmacotherapy, Phase 2 trial, Phase 3, practice-changing, Progression-Free Survival, Zanidatamab, Zymeworks

Jazz Pharmaceuticals; Zymeworks; zanidatamab; bispecific antibody; HER2; gastroesophageal adenocarcinoma; stomach cancer; phase 2 trial; phase 3 HERIZON-GEA-01; overall survival; progression-free survival; chemotherapy; practice-changing; Orphan Drug designation

Merck Continues Cuts: 204 Employees Laid Off in New Jersey

1 day ago talkbio0Tagged Biopharma Industry, Cautionary Warning, cost-cutting, Dosage Forms, Gardasil, global workforce reduction, Keytruda, layoffs, Merck, New Jersey, Rahway, restructuring

Merck; layoffs; New Jersey; Rahway; pharmaceutical; cost-cutting; restructuring; WARN notice; global workforce reduction; Keytruda; Gardasil; biopharma industry

Pressure On, Purpose Questioned as Second Round of FDA Priority Review Vouchers Revealed

1 day ago talkbio0Tagged Anemia, Sickle Cell, Biosimilars, Commissioner 's National Priority Voucher, Drug Approval, drug price, eli lilly, erbB-2 Receptor, Malignant neoplasm of lung, Obesity, Priority Review, public health medicine (field), Tuberculosis, Drug-Resistant, United States Food and Drug Administration, voucher program

FDA; Commissioner’s National Priority Voucher; priority review; drug approval; voucher program; Eli Lilly; Novo Nordisk; her2 lung cancer; obesity drugs; drug-resistant tuberculosis; sickle cell disease; biosimilars; public health; drug pricing; regulatory controversy

Genmab Discontinues ProfoundBio-Derived ADC GEN1107 After Acquisition, Paralleling J&J’s Ambrx Buyout Area Developments

1 day ago talkbio0Tagged AbbVie, Acquisition, Ambrx, Antibody-Drug Conjugates, Drug Development, GEN1107, Genmab, J&J, Johnson and Johnson, Neoplasms, ProfoundBio, PTK7, PTK7 protein, human

Genmab; ProfoundBio; antibody-drug conjugate (ADC); GEN1107; PTK7; Ambrx; Johnson & Johnson (J&J); oncology; drug development; biotech acquisition; AbbVie lawsuit

Sandoz Launches Tyruko (Natalizumab-Sztn), First Tysabri Biosimilar, in US After JCV Assay Delays

1 day ago talkbio0Tagged Approved, Biological Assay, Biosimilars, JC Virus, JCV, Leukoencephalopathy, Progressive Multifocal, Multiple Sclerosis, Polpharma Biologics, Progressive, sandoz, Tyruko, Tysabri, United States Food and Drug Administration

Sandoz; Tyruko; Tysabri biosimilar; natalizumab-sztn; multiple sclerosis (MS); biosimilar launch; JCV assay; progressive multifocal leukoencephalopathy (PML); FDA approval; Polpharma Biologics

Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama

5 days ago talkbio0Tagged Acquisition, bidding war, CVR, Glucagon-Like Peptide 1, Metsera, Nordisk, Obesity, Pfizer, regulatory certainty

Pfizer; Metsera; acquisition; Novo Nordisk; bidding war; obesity drugs; GLP-1; CVR; regulatory certainty

MacroGenics Stops Bispecific Development; Third Arc Bio Signs $840M Licensing Deal with Adagene

5 days ago talkbio0Tagged Adagene, Antibodies, Bispecific, Arc Bio, CD3 T cell, Clinical Trials, engagers, licensing agreement, lorigerlimab, MacroGenics, mCRPC, SAFEbody technology

MacroGenics; lorigerlimab; bispecific antibody; mCRPC; clinical trial halt; Third Arc Bio; Adagene; SAFEbody technology; CD3 T cell engagers; licensing agreement; biotech deals

Merck Q3 2025: Solid Organic Growth Across All Sectors

7 days ago talkbio0Tagged Acquisition, Animal Health, Gross margin, Keytruda, Merck, Neoplasms, new product, organic growth, Pharma, Q3 2025, Verona

Merck; Q3 2025; Organic growth; KEYTRUDA; Oncology; Animal Health; Verona Pharma acquisition; Gross margin; Revenue; New product launches

From Weight Loss to Hair Loss: The Search for the Next Blockbuster – Recent Developments and News (2024-2025)

1 week ago talkbio0Tagged Alopecia, Androgenetic Alopecia, baldness cure, blockbuster drugs, Glucagon-Like Peptide 1, Investments, minoxidil, pattern hair loss, Pelage Pharmaceuticals, PP405, Veradermics, Weight-Loss Agents

weight loss drugs; GLP-1; hair loss treatments; Pelage Pharmaceuticals; Veradermics; blockbuster drugs; pattern hair loss; baldness cure; minoxidil; PP405; androgenetic alopecia; biotech investment